Dr. Colin Bier

Dr. Colin Bier is responsible for Nonclinical Development, Pharmacology & Toxicology at Aquity Associates.  His expertise in designing, conducting, and executing preclinical toxicology and pharmacology studies supports Aquity’s vision of providing expert consulting to the life sciences industries.

He has held senior scientific and executive management positions in the contract research industry and has extensive regulatory experience (Health Protection Canada, US FDA, EMEA, and MHW) in preclinical and clinical drug development as well as diagnostics and medical devices. Dr. Bier has consulted for more than 60 biotechnology, emerging pharmaceutical, and medical device companies and has conducted due diligence investigations on more than 140 companies. Dr. Bier brings extensive management experience to Aquity’s leadership.

Dr. Bier is the Managing and Scientific Director of ABA BioResearch, an independent bioregulatory and preclinical toxicology consulting company. He received his doctorate in experimental pathology from Colorado State University as an NCI Fellow and then pursued additional training as a Medical Research Council Postdoctoral Fellow and the Dr. Douglas James Fellow in the Department of Pathology, McGill University.

Dr. Bier is on the scientific advisory board of three companies and serves as a director of two private companies as well as a hospital board.

cbier@aquityassociates.com
(514) 946-3449